[1] 中华医学会皮肤性病学分会真菌学组. 甲真菌病诊治指南(2008版)[J]. 中华皮肤科杂志,2008,41(12):844-845.
[2] 中华医学会皮肤性病学分会,中国中西医结合学会皮肤性病专业委员会,中国医师协会皮肤科医师分会.中国甲真菌病诊治指南(2015年版)[J]. 中国真菌学杂志,2015,10(2):118-125.
[3] 中国医师协会皮肤科医师分会真菌学亚专业委员会,中国中西医结合学会皮肤性病专业委员会真菌学组.甲真菌病的诊疗难点和个体化策略[J]. 中国真菌学杂志,2010,5(2):116-120.
[4] 王爱平,余进,万喆. 国内多中心甲真菌病病原菌流行病学调查[J]. 中国真菌学杂志,2015,10(4):197-202.
[5] GUPTA A K, GUPTA G, JAIN H C, et al. The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30000 patients visiting physicians' offices[J]. J Eur Acad Dermatol Venereol, 2016,30(9):1567-1572.
[6] KLAASSEN K M, DULAK M G, VAN DE KERKHOF P C, et al. The prevalence of onychomycosis in psoriatic patients: a systematic review[J]. J Eur Acad Dermatol Venereol, 2014,28(5):533-541.
[7] ROUZAUD C, HAY R, CHOSIDOW O, et al. Severe dermatophytosis and acquired or innate immunodeficiency: A review[J]. J Fungi (Basel), 2015,2(1):4.
[8] KOTRAJARAS R, CHONGSATHIEN S, ROJANAVANICH V, et al. Hendersonula toruloidea infection in Thailand[J]. Int J Dermatol, 1988,27(6):291-295.
[9] 余进,李若瑜.国内甲真菌病病原学的流行病学调查[J].中国真菌学杂志,2006,1(1):63-64.
[10] GUPTA A K, DAIGLE D, CARVIEL J L. The role of biofilms in onychomycosis[J]. J Am Acad Dermatol, 2016,74(6):1241-1246.
[11] VEIGA F F, DE CASTRO-HOSHINO L V, SATO F, et al. Fusarium oxysporum is an onychomycosis etiopathogenic agent[J]. Future Microbiol, 2018,13(3):1745-1756.
[12] 卫凤莲,温海,徐红,等. 7种甲真菌病致病菌的侵袭力比较[J]. 中国真菌学杂志,2007,2(6):333-338.
[13] HAY R J, BARAN R. Onychomycosis: a proposed revision of the clinical classification[J]. J Am Acad Dermatol, 2011,65(6):1219-1227.
[14] 岳学苹,石秀艳,陈伟,等. CFW荧光染色法在甲真菌病诊断中的应用研究[J]. 中国真菌学杂志,2018,13(1):8-10,45.
[15] GUPTA A K, DRUMMOND-MAIN C, COOPER E A, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment[J]. J Am Acad Dermatol, 2012, 66(3): 494-502.
[16] KONG X, TANG C, SINGH A, et al. Antifungal susceptibility and mutations in the squalene epoxidase gene in dermatophytes of the Trichophyton mentagrophytes species complex[J]. Antimicrob Agents Chemother, 2021,65(8):e0005621.
[17] SHAO J, WAN Z, LI R, et al. Species identification of dermatophytes isolated in China by matrix-assisted laser desorption ionisation-time-of-flight mass spectrometry[J]. Mycoses, 2020, 63(12): 1352-1361.
[18] 孙振燕,张思平,章婧,等. 甲真菌病皮肤镜表现及模式分析[J]. 中华皮肤科杂志, 2018,51(11):812-814.
[19] 王诗琪,李航,李若瑜.皮肤镜在甲真菌病与炎症性甲病诊断及鉴别诊断中的应用[J]. 中国皮肤性病学杂志,2020,34(12):1443-1448.
[20] FÁVERO M L D, BONETTI A F, DOMINGOS E L, et al. Oral antifungal therapies for toenail onychomycosis: a systematic review with network meta-analysis toenail mycosis: network meta-analysis[J]. J Dermatolog Treat, 2020,20(2):1-10.
[21] SIGURGEIRSSON B, ROSSEM K V, MALAHIAS S, et al. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis[J]. J Am Acad Dermatol, 2013,69(3):416-425.e1.
[22] WATANABE S, TSUBOUCHI I, OKUBO A. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study[J]. J Dermatol, 2018,45(10):1151-1159.
[23] ELEWSKI B, BRAND S, DEGENHARDT T, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail[J]. Br J Dermatol, 2021,184(2):270-280.
[24] 王爱平, 李若瑜. 5%盐酸阿莫罗芬搽剂在甲真菌病中的应用[J]. 中国真菌学杂志,2015,10(5):317-320.
[25] 王若珺,李若瑜,王爱平. 外用抗真菌药物治疗甲真菌病进展[J].中国真菌学杂志,2018,13(4):114-118.
[26] GUPTA A K, VERSTEEG S G. A critical review of improvement rates for laser therapy used to treat toenail onychomycosis[J]. J Eur Acad Dermatol Venereol, 2017, 31(7): 1111-1118.
[27] 聂振华,张宇,戴臻,等. 阿莫罗芬联合特比萘芬治疗甲真菌病的临床疗效观察[J]. 中国中西医结合皮肤性病学杂志,2004, 3(3):168-169.
[28] SIGURGEIRSSON B, OLAFSSON J H, STEINSSON J T, et al. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years[J]. J Eur Acad Dermatol Venereol, 2010, 24(8): 910-915. |
